Research programme: skin disorder therapeutics - Skinvisible Pharmaceuticals

Drug Profile

Research programme: skin disorder therapeutics - Skinvisible Pharmaceuticals

Latest Information Update: 17 Jun 2014

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Skinvisible Pharmaceuticals
  • Class Aminoquinolines; Imidazoles; Naphthalenes; Small molecules
  • Mechanism of Action Cell membrane modulators; Cholesterol synthesis inhibitors; Immunostimulants; Squalene monooxygenase inhibitors; Toll-like receptor 7 agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Preclinical Actinic keratosis; Basal cell cancer; Genital warts; Mycoses; Tinea

Most Recent Events

  • 28 May 2014 Imiquimod and terbinafine formulations are available for licensing as of 28 May 2014.
  • 28 May 2014 Preclinical trials in Actinic keratosis in USA (Topical)
  • 28 May 2014 Preclinical trials in Basal cell cancer in USA (Topical)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top